Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody

Maria Luisa Alegre, Alexander M. Collins, Virginia L. Pulito, Ruth A. Brosius, William C. Olson, Robert A. Zivin, Robert Knowles, J. Richard Thistlethwaite, Linda K. Jolliffe, Jeffrey A. Bluestone

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The binding specificity of the murine OKT3 has been transferred into a human antibody framework to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation, which has been correlated, in vivo, with the severe side effects observed in transplant recipients after the first administration of the mAb. T cell activation is thought to be triggered by the cross-linking mediated by the antibodies between T cells and Fc receptor-bearing cells. In this study, we introduced a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. This mutation generated a 100-fold decrease in the affinity of the antibody for the Fc receptor on U937 cells, without affecting Ag binding. In parallel, we observed a marked reduction in the T cell activation triggered by the mAb (proliferation, cell surface expression of early activation markers including Leu 23 and IL-2R, and release of TNF-α, IFN-γ, and granulocyte macrophage-CSF). In contrast, the mutated mAb retained suppressive properties similar to the gOKT3-5 mAb, as assessed by significant modulation of the T cell receptor complex and suppression of Ag-specific CTL activity. We conclude that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immununosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. This drug might achieve potent immunosuppression while minimizing acute toxicity in vivo and thus be useful in transplantation as well as in autoimmune diseases.

Original languageEnglish
Pages (from-to)3461-3468
Number of pages8
JournalJournal of Immunology
Volume148
Issue number11
StatePublished - Jun 1 1992

Fingerprint

Muromonab-CD3
Immunosuppressive Agents
Fc Receptors
T-Lymphocytes
Amino Acids
Mutation
T-Cell Antigen Receptor
Interleukin-23
U937 Cells
Antibody Affinity
Antibodies
Granulocytes
Leucine
Immunosuppression
Autoimmune Diseases
Glutamic Acid
Transplantation
Macrophages
Cell Proliferation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Alegre, M. L., Collins, A. M., Pulito, V. L., Brosius, R. A., Olson, W. C., Zivin, R. A., ... Bluestone, J. A. (1992). Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. Journal of Immunology, 148(11), 3461-3468.

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. / Alegre, Maria Luisa; Collins, Alexander M.; Pulito, Virginia L.; Brosius, Ruth A.; Olson, William C.; Zivin, Robert A.; Knowles, Robert; Thistlethwaite, J. Richard; Jolliffe, Linda K.; Bluestone, Jeffrey A.

In: Journal of Immunology, Vol. 148, No. 11, 01.06.1992, p. 3461-3468.

Research output: Contribution to journalArticle

Alegre, ML, Collins, AM, Pulito, VL, Brosius, RA, Olson, WC, Zivin, RA, Knowles, R, Thistlethwaite, JR, Jolliffe, LK & Bluestone, JA 1992, 'Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody', Journal of Immunology, vol. 148, no. 11, pp. 3461-3468.
Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. Journal of Immunology. 1992 Jun 1;148(11):3461-3468.
Alegre, Maria Luisa ; Collins, Alexander M. ; Pulito, Virginia L. ; Brosius, Ruth A. ; Olson, William C. ; Zivin, Robert A. ; Knowles, Robert ; Thistlethwaite, J. Richard ; Jolliffe, Linda K. ; Bluestone, Jeffrey A. / Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. In: Journal of Immunology. 1992 ; Vol. 148, No. 11. pp. 3461-3468.
@article{6b6b2e5e31084c15a1a278e64e856758,
title = "Effect of a single amino acid mutation on the activating and immunosuppressive properties of a {"}humanized{"} OKT3 monoclonal antibody",
abstract = "The binding specificity of the murine OKT3 has been transferred into a human antibody framework to reduce its immunogenicity. This {"}humanized{"} anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation, which has been correlated, in vivo, with the severe side effects observed in transplant recipients after the first administration of the mAb. T cell activation is thought to be triggered by the cross-linking mediated by the antibodies between T cells and Fc receptor-bearing cells. In this study, we introduced a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. This mutation generated a 100-fold decrease in the affinity of the antibody for the Fc receptor on U937 cells, without affecting Ag binding. In parallel, we observed a marked reduction in the T cell activation triggered by the mAb (proliferation, cell surface expression of early activation markers including Leu 23 and IL-2R, and release of TNF-α, IFN-γ, and granulocyte macrophage-CSF). In contrast, the mutated mAb retained suppressive properties similar to the gOKT3-5 mAb, as assessed by significant modulation of the T cell receptor complex and suppression of Ag-specific CTL activity. We conclude that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immununosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. This drug might achieve potent immunosuppression while minimizing acute toxicity in vivo and thus be useful in transplantation as well as in autoimmune diseases.",
author = "Alegre, {Maria Luisa} and Collins, {Alexander M.} and Pulito, {Virginia L.} and Brosius, {Ruth A.} and Olson, {William C.} and Zivin, {Robert A.} and Robert Knowles and Thistlethwaite, {J. Richard} and Jolliffe, {Linda K.} and Bluestone, {Jeffrey A.}",
year = "1992",
month = "6",
day = "1",
language = "English",
volume = "148",
pages = "3461--3468",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody

AU - Alegre, Maria Luisa

AU - Collins, Alexander M.

AU - Pulito, Virginia L.

AU - Brosius, Ruth A.

AU - Olson, William C.

AU - Zivin, Robert A.

AU - Knowles, Robert

AU - Thistlethwaite, J. Richard

AU - Jolliffe, Linda K.

AU - Bluestone, Jeffrey A.

PY - 1992/6/1

Y1 - 1992/6/1

N2 - The binding specificity of the murine OKT3 has been transferred into a human antibody framework to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation, which has been correlated, in vivo, with the severe side effects observed in transplant recipients after the first administration of the mAb. T cell activation is thought to be triggered by the cross-linking mediated by the antibodies between T cells and Fc receptor-bearing cells. In this study, we introduced a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. This mutation generated a 100-fold decrease in the affinity of the antibody for the Fc receptor on U937 cells, without affecting Ag binding. In parallel, we observed a marked reduction in the T cell activation triggered by the mAb (proliferation, cell surface expression of early activation markers including Leu 23 and IL-2R, and release of TNF-α, IFN-γ, and granulocyte macrophage-CSF). In contrast, the mutated mAb retained suppressive properties similar to the gOKT3-5 mAb, as assessed by significant modulation of the T cell receptor complex and suppression of Ag-specific CTL activity. We conclude that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immununosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. This drug might achieve potent immunosuppression while minimizing acute toxicity in vivo and thus be useful in transplantation as well as in autoimmune diseases.

AB - The binding specificity of the murine OKT3 has been transferred into a human antibody framework to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation, which has been correlated, in vivo, with the severe side effects observed in transplant recipients after the first administration of the mAb. T cell activation is thought to be triggered by the cross-linking mediated by the antibodies between T cells and Fc receptor-bearing cells. In this study, we introduced a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. This mutation generated a 100-fold decrease in the affinity of the antibody for the Fc receptor on U937 cells, without affecting Ag binding. In parallel, we observed a marked reduction in the T cell activation triggered by the mAb (proliferation, cell surface expression of early activation markers including Leu 23 and IL-2R, and release of TNF-α, IFN-γ, and granulocyte macrophage-CSF). In contrast, the mutated mAb retained suppressive properties similar to the gOKT3-5 mAb, as assessed by significant modulation of the T cell receptor complex and suppression of Ag-specific CTL activity. We conclude that this anti-CD3 mAb bearing a single amino acid mutation in its Fc portion retains important immununosuppressive properties, while exhibiting significantly less T cell activation than OKT3 in vitro. This drug might achieve potent immunosuppression while minimizing acute toxicity in vivo and thus be useful in transplantation as well as in autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=0026580592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026580592&partnerID=8YFLogxK

M3 - Article

C2 - 1534096

AN - SCOPUS:0026580592

VL - 148

SP - 3461

EP - 3468

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -